Related Experiment Videos
Effectiveness of short-course, intermittent chemotherapy for tuberculosis in young infants aged less than 6 months
1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara-Turkey.
Insights
Short-course intermittent chemotherapy, including isoniazid and rifampin, proved safe and effective for treating tuberculosis in infants under six months. This regimen showed no relapses in a long-term follow-up study.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Tuberculosis (TB) in infants presents unique treatment challenges.
- Standard TB chemotherapy regimens may not be optimal for neonates and young infants.
- Limited data exists on the efficacy of short-course intermittent chemotherapy in this age group.
Purpose of the Study:
- To evaluate the safety and efficacy of a short-course intermittent chemotherapy regimen for treating tuberculosis in infants less than 6 months of age.
- To assess long-term outcomes, including relapse rates, following treatment completion.
Main Methods:
- A cohort of 15 newly diagnosed infants (<6 months) received daily isoniazid and rifampin (with or without streptomycin) for 15 days.
- Treatment continued with twice-weekly isoniazid and rifampin for 8.5 months.
- Patients were followed for 1 to 10 years post-treatment.
Main Results:
- No infant in the study experienced a relapse of tuberculosis after completing the treatment regimen.
- The treatment regimen was administered to young infants, suggesting potential tolerability.
Conclusions:
- Short-course intermittent chemotherapy demonstrates promising safety and efficacy for treating tuberculosis in young infants.
- This treatment approach may offer a viable alternative for pediatric TB management.
Abstract:
In order to determine the efficacy of short-course intermittent chemotherapy for tuberculosis in young infants less than 6 months of age, 15 newly diagnosed infants were treated with isoniazid (10-15 mg/kg) and rifampin (10-15 mg/kg), with/without streptomycin (30 mg/kg), daily for 15 days followed by similar doses of isoniazid and rifampin twice a week for another 8.5 months. The follow-up period ranged from 1 to 10 years. No patient demonstrated relapse following the termination of the treatment. These results suggest that short-course, intermittent treatment may be safe and effective for treating tuberculosis in young infants.